|
Schizophrenia
|
0.540 |
AlteredExpression
|
disease |
LHGDN |
Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis.
|
19034380 |
2009 |
|
Schizophrenia
|
0.540 |
GeneticVariation
|
disease |
BEFREE |
The use of clinical sub-phenotypes such as psychotic features or other potential schizophrenia/BP overlap variables including cognitive abnormalities and poor functioning might shed further light on the potential subtypes of illness most closely associated with genetic variation in YWHAH.
|
19160447 |
2009 |
|
Schizophrenia
|
0.540 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that the polymorphisms at the NPY and YWHAH genes are unlikely to be linked with genetic susceptibility to schizophrenia.
|
15814194 |
2005 |
|
Schizophrenia
|
0.540 |
Biomarker
|
disease |
RGD |
The genetic association database.
|
15118671 |
2004 |
|
Schizophrenia
|
0.540 |
GeneticVariation
|
disease |
BEFREE |
14-3-3 protein eta chain gene (YWHAH) polymorphism and its genetic association with schizophrenia.
|
10206237 |
1999 |
|
Bipolar Disorder
|
0.310 |
Biomarker
|
disease |
PSYGENET |
We investigated the association of YWHAH with BP in a large sample, consisting of 1211 subjects from 318 nuclear families including 554 affected offspring.
|
19160447 |
2009 |
|
Bipolar Disorder
|
0.310 |
Biomarker
|
disease |
BEFREE |
We investigated the association of YWHAH with BP in a large sample, consisting of 1211 subjects from 318 nuclear families including 554 affected offspring.
|
19160447 |
2009 |
|
Alloxan Diabetes
|
0.300 |
Therapeutic
|
disease |
CTD_human |
14-3-3 protein regulates Ask1 signaling and protects against diabetic cardiomyopathy.
|
18342293 |
2008 |
|
Diabetes Mellitus, Experimental
|
0.300 |
Therapeutic
|
disease |
CTD_human |
14-3-3 protein regulates Ask1 signaling and protects against diabetic cardiomyopathy.
|
18342293 |
2008 |
|
Cardiomyopathies, Primary
|
0.300 |
Therapeutic
|
group |
CTD_human |
14-3-3 protein regulates Ask1 signaling and protects against diabetic cardiomyopathy.
|
18342293 |
2008 |
|
Myocardial Diseases, Secondary
|
0.300 |
Therapeutic
|
group |
CTD_human |
14-3-3 protein regulates Ask1 signaling and protects against diabetic cardiomyopathy.
|
18342293 |
2008 |
|
Streptozotocin Diabetes
|
0.300 |
Therapeutic
|
disease |
CTD_human |
14-3-3 protein regulates Ask1 signaling and protects against diabetic cardiomyopathy.
|
18342293 |
2008 |
|
Cardiomyopathies
|
0.300 |
Therapeutic
|
group |
CTD_human |
14-3-3 protein regulates Ask1 signaling and protects against diabetic cardiomyopathy.
|
18342293 |
2008 |
|
Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
To our knowledge, this is the first study to identify the 14-3-3 eta gene as a tumor suppressor and that its expression is suppressed in colon tumors by DNA hypermethylation.
|
26518883 |
2015 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
The pro-apoptotic CD14, TIA1, and ITGB2 were down-regulated in more than 50% of the tumor cultures after treatment with doxorubicin, as was the antiapoptotic YWHAH.
|
18959781 |
2008 |
|
Malignant neoplasm of prostate
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Eleven variants within 10 genes (CCNC, CCND3, CCNG1, CCNT2, CDK6, MDM2, SKP2, WEE1, YWHAB, YWHAH) in the European-American population and nine variants in 7 genes (CCNG1, CDK2, CDK5, MDM2, RB1, SMAD3, TERF2) in the African-American population were found to be associated with aggressive PCa using at least one model.
|
26708993 |
2016 |
|
Prostate carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Eleven variants within 10 genes (CCNC, CCND3, CCNG1, CCNT2, CDK6, MDM2, SKP2, WEE1, YWHAB, YWHAH) in the European-American population and nine variants in 7 genes (CCNG1, CDK2, CDK5, MDM2, RB1, SMAD3, TERF2) in the African-American population were found to be associated with aggressive PCa using at least one model.
|
26708993 |
2016 |
|
Colonic Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
To our knowledge, this is the first study to identify the 14-3-3 eta gene as a tumor suppressor and that its expression is suppressed in colon tumors by DNA hypermethylation.
|
26518883 |
2015 |
|
Creutzfeldt-Jakob disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
A polymorphism in the YWHAH gene encoding 14-3-3 eta that is not associated with sporadic Creutzfeldt-Jakob disease (CJD).
|
21739144 |
2012 |
|
Creutzfeldt-Jakob Disease, Sporadic
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
This finding indicates that YWHAH 753 G/A polymorphism is unlikely to be linked to genetic susceptibility or have a modifying effect in sCJD.
|
21739144 |
2012 |
|
Other Creutzfeldt-Jakob disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
A polymorphism in the YWHAH gene encoding 14-3-3 eta that is not associated with sporadic Creutzfeldt-Jakob disease (CJD).
|
21739144 |
2012 |
|
Mental disorders
|
0.010 |
GeneticVariation
|
group |
BEFREE |
We have provided additional evidence for association of variants in YWHAH with major mental illness.
|
19160447 |
2009 |
|
Inflammation
|
0.010 |
Biomarker
|
phenotype |
LHGDN |
Detection of high levels of 2 specific isoforms of 14-3-3 proteins in synovial fluid from patients with joint inflammation.
|
17611984 |
2007 |
|
Myeloid Leukemia
|
0.010 |
PosttranslationalModification
|
disease |
LHGDN |
MADM, a novel adaptor protein that mediates phosphorylation of the 14-3-3 binding site of myeloid leukemia factor 1.
|
12176995 |
2002 |
|
Parkinson Disease
|
0.010 |
Biomarker
|
disease |
LHGDN |
We investigated the 14-3-3 eta (YWHAH) gene by mutation analysis and association studies as it maps to human chromosome 22q12.1-q13.1, a region which has been recently implicated in PD and carried out immunohistochemical studies of Lewy bodies with two different 14-3-3 eta antibodies.
|
12480176 |
2002 |